Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -0.74% 67.00p 66.00p 68.00p 67.50p 67.00p 67.50p 42,991 09:52:33
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.6 -8.9 -10.1 - 96.14

Angle Share Discussion Threads

Showing 49626 to 49647 of 49650 messages
Chat Pages: 1986  1985  1984  1983  1982  1981  1980  1979  1978  1977  1976  1975  Older
DateSubjectAuthorDiscuss
20/5/2019
11:33
Thought that we might get a bit of feedback from last week’s conference, even on the Twitter page?
semper vigilans
18/5/2019
15:15
htTps://ascopost.com/videos/2019-genitourinary-cancers-symposium/howard-scher-on-circulating-tumor-cells-as-a-surrogate-endpoint-for-survival/
waterloo01
16/5/2019
19:25
Pretty sure that the company you are referencing had a similar update recently on clustered CTCs as being the next step from the same source.. hmmm!!
l0ngterm
15/5/2019
22:02
https://www.dailymail.co.uk/health/article-7032835/Blood-test-determine-cancer-likely-spread-fast.html
ayl30
15/5/2019
15:33
Nice reversal- bullish New trend?
eddiegoldstein
15/5/2019
15:21
True Jelenko :)
alloa2003
15/5/2019
15:05
Or the buyer Not!
jelenko
15/5/2019
14:45
Looks to me like the seller may have finished
alloa2003
14/5/2019
19:08
hxxps://www.eacr.org/user_uploads/files/LiBi19%20A5%20Programme%20Book%20ONLINE.pdf A mass of Parsortix related papers at the EACR conference on liquid biopsy in Bergamo, which kicks off tomorrow. Angle is exhibiting and papers are listed from many of the research institutes - MD anderson, Athens, Dusseldorf, Basle, Manchester, who we know are using Parsortix. I think we are due more RNS announcements in the next few days.
auction12
14/5/2019
18:18
So the rather large sell (now showing) from early this morning must have been the reason why the share price dropped.
maxie23
14/5/2019
12:25
I'd suggest June for that Semper.
jelenko
14/5/2019
09:03
Can’t be far away from submission to FDA.
semper vigilans
14/5/2019
08:45
AGL recruiting in Canada and US
bagpuss67
13/5/2019
09:34
Sk, The value of Parsortix's in HER2 testing lies in the potential of a licensing deal with Abbott. If/when that happens, I'm sure both companies are more than capable of working to improve/scale up the process. The FDA constantly deal with modifications to medical devices, it's standard stuff. Regarding the process and the complexity, I completely agree that over time it will need improvements to scale up and I'm sure that's true of every medical device that's ever been invented. In the meantime, the question is whether hospitals will wait and hope that a one button press, fully automated system eventually evolves or will they want to buy now? Will they believe that their intelligent, trained staff are able to deal with the complexities you have listed and that it's worth the effort or will they decide to wait and leave patients to live with the uncertainty that their HER2 status may have changed and they may be on the wrong treatment?
bermudashorts
13/5/2019
08:38
SK - how many key presses did you do in order to type post 620? Was it onerous? I think you are trying to make a process, which is being used with stunning results by various research establishments all over the world, appear much more hassle than it is.
impvesta
13/5/2019
05:35
Blimey. I could write a 100 point process for taking a photocopy at work. All that inserting more paper into the paper tray, adjusting the settings and changing of toner cartridges. Probably far more than that if l include all the extra procedures involved in clearing the inevitable paper jams. Can't believe photocopiers have ever passed FDA or been taken up for general use tbh as they're so complicated.
mikepompeyfan
13/5/2019
05:33
I suggest you research guardiant further, because the value isn't in the capture. It is in the analysis, hence the lab based tests. The deficiencies are in the capture.
l0ngterm
13/5/2019
03:45
If there's a compelling application, ease of use won't matter very much. If there isn't a compelling application, Angle has no future anyway.I wonder how much of Angle's share price strength this year was driven by the blockbuster Guardant IPO? Both good news and bad: cfDNA is taking a big commercial lead but selling to Guardant is a new exit possibility.IMHO, Angle should seriously consider raising a large sum of cash on Nasdaq and trying to develop fetal cells themselves. They need more runway to get through the gap between FDA approval and meaningful sales.
mirako
12/5/2019
22:58
Sk: I agree, I doubt angle will be here after approval. Someone will buy it cheap if successful, we hopefully will all reminisce and moan about them selling us out at about £5 a share. Then pause and say yeah, we helped.
l0ngterm
12/5/2019
22:50
would have thought that technician time is cheap compared with the cost of the drugs themselves; even if it takes a couple of days to produce the result; looks as though a new antibody to her2 expressing tumours, margetuximab, with improved progression free survival, in the SOPHIA trial, vs herceptin will soon be on the market and no doubt much, much more expensive than the already expensive herceptin.
mw8156
12/5/2019
22:46
Yes, but valuing a company is about more than that
sicilian_kan
12/5/2019
22:45
SK: do you agree if CTCs can be harvested and then drugs tested against them it is a positive?
l0ngterm
Chat Pages: 1986  1985  1984  1983  1982  1981  1980  1979  1978  1977  1976  1975  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190521 12:56:15